With HELIOS-3 Phase 3 trial for AXPAXLI now on its way, we could be looking at a major winner in the future. This treatment could completely change how diabetic retinal diseases are managed if it proves successful. That's huge! I know there's a big if in there, but there's a bigger payout in this risk.
There are no replies in this thread yet. Be the first to post a reply below: